Tradestie Institutional Equity Comparison Engine

SABS vs PLUR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SABS Overall Edge

SABS Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SAB Biotherapeutics, Inc. Common Stock (SABS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PLUR counters with relative strength in Valuation. Fundamentally, SABS trades at N/M Forward P/E with 0.0% operating margin (-62.4% YoY revenue) versus PLUR at 3.6x Forward P/E and -2454.5% operating margin (-15.8% YoY). In options structure, SABS sits in SURGE (17th %ile IV; Dealer Gamma Walls on Pro) against PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PLUR
SABS N/M vs PLUR 3.6x Fwd P/E
Growth & Margin Winner SABS
Op Margin 0.0% vs -2454.5% ยท YoY -62.4% vs -15.8%
Momentum & Technical Winner SABS
1Y -10.0% vs -78.8% ยท 52W Pos 18% vs 2%
Options & Structure Winner SABS
SURGE (17th %ile IV) vs UNCLASSIFIED (N/A IV)
SABS NASDAQ
SAB Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.92
-2.83% 1D
Market Cap $266.7M
1M Return +12.12%
1Y Return -10.03%
Forward P/E N/M
Unified AI Score
32.4 / 100 SELL
Tech 15.0 Fund 40.0 Flow 63.0 Mom 50.0
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
1M Return +11.09%
1Y Return -78.78%
Forward P/E 3.6x
Unified AI Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SABS -10.03% PLUR -78.78% Spread: +65.5 pp (SABS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SABS Revenue PLUR Revenue SABS Op. Margin PLUR Op. Margin Margin Edge
FY2019 N/A $0M N/A -65800.0% PLUR
FY2020 $60M $0M 37.2% -128156.5% SABS
FY2021 $60M N/A -22.0% N/A SABS
FY2022 $20M $0M -121.0% -17774.8% SABS
FY2023 $0M $0M -1700.6% -9493.4% SABS
FY2024 $0M $0M -3244.9% -6796.9% SABS
FY2025 N/A $0M N/A -1659.9% PLUR
FY2026 N/A $0M N/A -2454.5% PLUR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SABS (6) vs PLUR (3)
Institutional Metric SABS PLUR Criterion Row Winner
Market Capitalization Scale $266.7M $15.1M Larger Scale SABS
Trailing P/E Ratio Valuation N/M 3.6x Lower Multiple PLUR
Forward P/E Ratio Valuation N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY) Growth -62.4% -15.8% Higher Growth PLUR
Operating Margin (TTM) Profitability 0.0% -2454.5% Higher Margin SABS
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -42.8% -1022.0% Higher ROE SABS
52-Week Range Position Momentum 18% ($2โ€“$5) 2% ($1โ€“$5) Stronger Trend SABS
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 76% Vol 0.80ฮฒ ยท 102% Vol Lower Realized Risk SABS
Unified Institutional Score Composite Signal 32.4 / 100 (SELL) 28.8 / 100 (SELL) Higher Composite SABS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SABS vs PLUR Buy Guide
SABS SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live SABS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PLUR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SABS nor PLUR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.